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Abstract
Aims/hypothesis We examined the effect of a standardised sympathetic stimulus, incremental adrenaline (epinephrine) infusion
on cardiac repolarisation in individuals with type 1 diabetes with normal autonomic function, subclinical autonomic neuropathy
and established autonomic neuropathy.
Methods Ten individuals with normal autonomic function and baroreceptor sensitivity tests (NAF), seven with subclinical
autonomic neuropathy (SAN; normal standard autonomic function tests and abnormal baroreceptor sensitivity tests); and five
with established cardiac autonomic neuropathy (CAN; abnormal standard autonomic function and baroreceptor tests) underwent
an incremental adrenaline infusion. Saline (0.9% NaCl) was infused for the first hour followed by 0.01 μg kg−1 min−1 and
0.03 μg kg−1 min−1 adrenaline for the second and third hours, respectively, and 0.06 μg kg−1 min−1 for the final 30 min. High
resolution ECG monitoring for QTc duration, ventricular repolarisation parameters (T wave amplitude, T wave area symmetry
ratio) and blood sampling for potassium and catecholamines was performed every 30 min.
Results Baseline heart rate was 68 (95% CI 60, 76) bpm for the NAF group, 73 (59, 87) bpm for the SAN group and 84 (78, 91)
bpm for the CAN group. During adrenaline infusion the heart rate increased differently across the groups (p = 0.01). The
maximum increase from baseline (95% CI) in the CAN group was 22 (13, 32) bpm compared with 11 (7, 15) bpm in the
NAF and 10 (3, 18) bpm in the SAN groups. Baseline QTc was 382 (95% CI 374, 390) ms in the NAF, 378 (363, 393) ms in the
SAN and 392 (367, 417) ms in the CAN groups (p = 0.31). QTc in all groups lengthened comparably with adrenaline infusion.
The longest QTc was 444 (422, 463) ms (NAF), 422 (402, 437) ms (SAN) and 470 (402, 519) ms (CAN) (p = 0.09). T wave
amplitude and T wave symmetry ratio decreased and the maximum decrease occurred earlier, at lower infused adrenaline
concentrations in the CAN group compared with NAF and SAN groups. AUC for the symmetry ratio was different across the
groups and was lowest in the CAN group (p = 0.04). Plasma adrenaline rose and potassium fell comparably in all groups.
Conclusions/interpretation Participants with CAN showed abnormal repolarisation in some measures at lower adrenaline
concentrations. This may be due to denervation adrenergic hypersensitivity. Such individuals may be at greater risk of cardiac
arrhythmias in response to physiological sympathoadrenal challenges such as stress or hypoglycaemia.
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Introduction
Cardiac autonomic neuropathy (CAN) is a serious complica-
tion of diabetes associated with increased rates of cardiac
arrhythmias and sudden death [1]. Individuals with CAN
exhibit intracardiac sympathetic imbalance due to cardiac
parasympathetic denervation and initial sympathetic hyper-
sensitivity leading to progressive sympathetic denervation
[2]. These mechanisms might combine with the effects of
hypoglycaemia to increase pro-arrhythmic risk and could
identify CAN as a potential risk factor for sudden unexpected
nocturnal deaths in type 1 diabetes, also known as the ‘dead-
in-bed’ syndrome [3]. We previously tested this hypothesis in
a study involving experimental hypoglycaemia in participants
with type 1 diabetes [4]. Paradoxically, individuals with CAN
showed smaller increase in QT interval duration compared to
those with normal autonomic function. However, they also
had attenuated sympathoadrenal responses.
In the current study, we aimed to investigate whether type 1
diabetic individuals with established autonomic neuropathy or
subclinical autonomic neuropathy (SAN) would develop
greater changes in cardiac repolarisation compared to those
with normal autonomic function, when exposed to a standard
sympathetic stimulus.
Methods
Research design
Individuals with type 1 diabetes, 14 men and eight women,
aged between 18 and 50 years were recruited. Exclusion
criteria included ischaemic heart disease, peripheral vascular
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disease, cerebrovascular disease, pregnancy, thyrotoxicosis,
epilepsy or seizure disorder, asthma, visual impairment due
to retinopathy, renal impairment due to nephropathy or current
treatment with salbutamol orβ-blockers. All participants gave
written informed consent. The study protocol was approved
by the North Sheffield Research Ethics committee.
Standard autonomic function tests were performed. See
electronic supplementary material (ESM) Methods: Standard
autonomic function tests for details. Responses outside age-
adjusted normal ranges [5] in two or more tests were classified
as abnormal standard autonomic function tests. Baroreceptor
sensitivity (BRS) was calculated using the sequence method
[6] (see ESMMethods: Baroreceptor sensitivity). BRS values
lower than the 5th centile of age- and sex-adjusted ranges [7]
were classed as abnormal. Individuals were divided into three
groups: group 1—normal autonomic function (NAF; normal
autonomic function tests and normal BRS); group 2—SAN
(normal autonomic function tests but abnormal BRS) [6]; and
group 3—established CAN (abnormal autonomic function
and BRS tests).
Adrenaline infusions
Participants were admitted in the morning. Blood glucose was
maintained between 4 and 15 mmol/l using a low dose intra-
venous infusion of insulin (Human Actrapid, Novo Nordisk
Pharmaceuticals, Crawley, UK) or boluses of 20% glucose
(Freeflex, Fresenius Kabi, Runcorn, UK). Arterialised venous
blood samples were collected from a retrograde cannula with
the hand placed in a heated chamber at 50°C. The participants
then received an incremental adrenaline (epinephrine) infu-
sion: saline (0.9% NaCl) infusion for the first hour, followed
by adrenaline infusion at 0.01 μg kg−1 min−1 for the second
hour, 0.03 μg kg−1 min−1 for the third hour and finally
0.06 μg kg−1 min−1 for 30 min.
Plasma adrenaline, serum potassium, BP and heart rate
were measured at baseline, at 30 min intervals during the
study and 30 min after completion of the infusion (see ESM
Methods: Biochemical analysis).
ECG measurements
Five minute high resolution ECGs were recorded at 30 min
intervals to determine parameters of cardiac repolarisation:
QTc, T wave amplitude and T wave area symmetry ratio.
ECG was recorded from three bipolar orthogonal electrodes
and parameters of cardiac repolarisation were extracted from
the combined composite wave. These included the QTc inter-
val duration and parameters describing the morphology of the
Twave: Twave area symmetry ratio [8] and Twave amplitude
normalised to baseline values. The Hodges formula was used
to correct QT for heart rate (QTc). See ESM Methods: ECG
measurements for further details.
Statistical analysis
Adrenaline, potassium and cardiac repolarisation responses
during the adrenaline infusion were described by summary
measures for comparison between groups: AUC, time of the
maximum (or minimum), absolute maximum (minimum),
largest change from baseline and overall standardised variabil-
ity. Groups were compared using analysis of variance where
the underpinning assumptions were met or Kruskal–Wallis
test. Data are presented as mean (SD) or mean (95% CI). A
p value <0.05 was classed as significant. Statistical analysis
was performed using SPSS 22 (IBM, Armonk, NY, USA). For
details and power analysis see ESM Methods: Statistical
analysis.
Results
Participant characteristics
Ten participants with NAF, seven with SAN and five with
CAN participated in the study. Their mean age (SD) was 37
(6), 30 (6) and 38 (5) years, respectively (p = 0.04), their BMI
(SD) was 24 (2), 26 (3) and 29 (5) kg/m2, respectively (p =
0.05) and the male to female ratio was 8/2, 6/1 and 0/5, respec-
tively (p = 0.005). Baseline adrenaline levels (SD) were differ-
ent across the groups: 0.38 (0.17), 0.28 (0.16) and 0.21 (0.07)
nmol/l in the NAF, SAN and CAN groups, respectively (p =
0.04) (ESM Table 1).
Biochemical analysis
Plasma adrenaline rose in all groups with no differences
between the groups (Fig. 1a and ESM Table 2). Mean (95%
CI) baseline adrenaline concentration for all participants was
0.34 (0.25, 0.42) nmol/l and reached a maximum 4.78 (4.08,
5.47) nmol/l at 210 min. Serum potassium fell comparably in
all groups (ESM Table 3). Mean baseline potassium concen-
tration for all participants was 4.19 (4.04, 4.35) mmol/l and
decreased to 3.21 (3.10, 3.33) mmol/l at 210 min.
Physiological variables
Baseline heart rate was 68 (95% CI 60, 76) bpm for the NAF
group, 73 (59, 87) bpm for the SAN group and 84 (78, 91)
bpm for the CAN group (p = 0.06, ESM Table 4). Heart rate
increase from baseline was different across the groups: 22 (13,
32) bpm in the CAN compared with 11 (7, 15) bpm in the
NAF and 10 (3, 18) bpm in the SAN groups (p = 0.01).
Systolic and diastolic BP and their changes were comparable
(ESM Table 1 and ESM Results: Physiological variables).
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Changes in ventricular repolarisation
ECG waveforms at baseline and during adrenaline infusion
are presented in Fig. 2 for one individual with NAF (Fig. 2a)
and one with CAN (Fig. 2b). There was a decrease in Twave
amplitude and the T waves became more symmetric with
increased dose of adrenaline. In CAN the highest dose of
adrenaline resulted in notched T waves (Fig. 2b, d) and the
abnormal changes in morphology started at lower dose of
adrenaline (Fig. 2d).
QTc interval duration Baseline QTc was 382 (95% CI 374,
390) ms in the NAF, 378 (363, 393) ms in the SAN and 392
(367, 417) ms in the CAN groups (p = 0.31) (Fig. 1b and ESM
Table 1). QTc in all groups lengthened comparably with adren-
aline infusion (ESM Table 5). The longest QTc was 444 (422,
463) ms (NAF), 422 (402, 437) ms (SAN) and 470 (402, 519)
ms (CAN) (p = 0.09).
Normalised T wave amplitude and T wave area symmetry
ratio Amplitude of the Twave progressively decreased across
all groups to about 50% of its baseline value (ESM Table 6).
Time of minimum was different across the groups: 201 (95%
CI 187, 215) min (NAF), 176 (151, 201) min (SAN) and 120
(29, 211) min (CAN) (p = 0.02). The baseline T wave area
symmetry ratio was comparable in the three groups (ESM
Table 7). During the adrenaline infusion the T waves became
more symmetric (decrease in symmetry ratio). Symmetry ratio
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equal to number 1 indicates perfect symmetry around the peak
of the Twave. AUCwas lowest in the CAN group (1.19 [95%
CI 1.12, 1.25]) compared with the NAF (1.36 [1.19, 1.53])
and SAN (1.39 [1.22, 1.56]) groups (p = 0.04). Time of mini-
mum was shortest in the CAN group (p = 0.01).
Discussion
In this study, we used the infusion of adrenaline as a
standardised sympathetic stimulus to investigate the effect
on cardiac repolarisation among type 1 diabetic individuals
with normal autonomic function, subclinical autonomic
neuropathy and established autonomic neuropathy. We noted
significant changes in Twave morphology in the CAN group.
QT interval correction by adjusting for heart rate can lead to
an artefactual increase in QT intervals, especially at high heart
rates. Thus the morphology parameters used in this study
better characterise the overall repolarisation characteristics
since they are less rate dependent [8]. The maximum changes
in these parameters occurred at lower infused adrenaline
concentrations in individuals with CAN despite comparable
adrenaline levels. We also noted abnormal notched Twaves in
the CAN group. These changes might be explained by dener-
vation adrenergic hypersensitivity, a phenomenon that is well
described in diabetic autonomic neuropathy [9]. We found no
evidence that the response to adrenaline infusion was different
in the SAN group compared with the NAF group. This might
be due to a functional defect in SAN in contrast to a structural
one in CAN.
We did not reach target sample sizes in the SAN and CAN
groups despite screening over 90 potential participants.
Established autonomic neuropathy is relatively uncommon
in young individuals with type 1 diabetes and patients with
ischaemic heart disease and renal disease were not included
for safety/ethical reasons. Thus, we cannot exclude the possi-
bility of a type 2 error. Imbalanced sex and BMI characteris-
tics could affect some results of our study. While QTc is influ-
enced by sex, T wave symmetry is rate- and sex-independent
and less likely to be affected [8]. No corrections for multiple
testing could lead to inflated false positive observations in this
study. The statistical data, however, were not interpreted as
definite but rather indicative of repolarisation measures that
best describe and classify the changes during adrenaline
infusion.
In conclusion, type 1 diabetic individuals with CAN may
be more vulnerable to cardiac arrhythmias when exposed to
sympathoadrenal challenges. Screening for autonomic
dysfunction using bedside tests could identify patients with
diabetes at increased risk of cardiac arrhythmia during
hypoglycaemia. Further studies with larger numbers and
better balanced groups are required to confirm our findings.
Those affected might theoretically benefit from β-blockers
although such a treatment might also have the potential to
increase the risk of hypoglycaemia in those with impaired
hypoglycaemia awareness.
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